Abstract
Inherited disorders of hemoglobin remain desirable targets for genetically based therapies. That stem cell replacement reverses the phenotype of both thalassemia and sickle cell anemia has been well established through allogeneic bone marrow transplantation studies, yet significant toxicities and finite donor availability limit this approach to a minority of affected individuals. Genetically based strategies that have as their goal addition of a normal copy of the human beta-globin gene along with key regulatory sequences to autologous hematopoietic stem cells represent a viable alternative to allogeneic transplantation, but this approach has been impeded by formidable obstacles over the last decade. Large animal models have become the standard for the development of clinically relevant gene addition strategies, and significant progress in the techniques used to deliver potentially therapeutic genes has been achieved. The clinical application of such strategies may be close at hand, at least for disorders in which modest level, constitutive expression is sufficient to correct the phenotype. For the thalassemias and hemoglobinopathies, complex, regulated, lineage specific expression of the beta-globin gene at relatively high lev...Continue Reading
Citations
Apr 5, 2002·The Journal of Gene Medicine·Michel Sadelain
Oct 23, 2004·Best Practice & Research. Clinical Haematology·Michel SadelainIsabelle Rivière
Sep 21, 2002·Lancet·Elliott Vichinsky
Feb 19, 2009·Human Gene Therapy·Jun HayakawaJohn F Tisdale
Mar 29, 2006·Current Opinion in Hematology·Michel Sadelain
Aug 17, 2005·Journal of Virology·Hongjie WangAndré Lieber
Nov 13, 2004·Stem Cells·Peiman HemattiJohn F Tisdale
Jul 21, 2011·Pediatric Reports·Antonio CaoRenzo Galanello
May 19, 2007·Biochemistry·Jianhui ZhuClifford J Steer
Dec 13, 2005·Annals of the New York Academy of Sciences·Michel SadelainIsabelle Riviere
Jun 24, 2004·Vox Sanguinis·M Sadelain
Mar 5, 2003·British Journal of Haematology·Persis J AmroliaSally C Davies
Jan 27, 2007·Stem Cells·Jerry C ChengKathleen M Sakamoto
Apr 16, 2008·British Journal of Haematology·Leszek Lisowski, Michel Sadelain
Jun 29, 2011·British Journal of Haematology·Jorge Mansilla-SotoMichel Sadelain
Mar 15, 2012·Expert Opinion on Biological Therapy·Roberto Gambari
Jan 9, 2003·Expert Opinion on Biological Therapy·Frank C MariniMichael Andreeff
Mar 7, 2007·Biochemical and Biophysical Research Communications·Hai-sheng ZhouChih-chuan Liang
Feb 19, 2017·Stem Cells Translational Medicine·Phetcharat PhanthongSuradej Hongeng
Aug 30, 2002·Leukemia·Z LiC Baum
Jun 21, 2013·Expert Review of Hematology·Laura BredaRoberto Gambari
Oct 24, 2002·Blood·Marla M VacekRyszard Kole
Oct 31, 2002·Blood·William R Staplin, Joseph A Knezetic
Dec 14, 2002·Blood·Stefano RivellaMichel Sadelain
Mar 6, 2002·Blood·Chad MayMichel Sadelain